Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer

Area of Science:

• Oncology
• Radiation Oncology

Background:

• Colorectal cancer (CRC) is a leading cause of cancer mortality globally.
• Metastatic disease is the primary determinant of poor prognosis in CRC.
• Oligometastatic disease presents an opportunity for curative-intent local therapies.

Purpose of the Study:

• To review the current evidence for Stereotactic Ablative Radiotherapy (SABR) in oligometastatic colorectal cancer (CRC).
• To explore emerging strategies to enhance SABR efficacy and patient selection for oligometastatic CRC.

Main Methods:

• Review of existing randomized trials (e.g., SABR-COMET) and prospective studies (e.g., SABR-5) on SABR for oligometastatic disease.
• Analysis of challenges including CRC radioresistance, anatomical site variations, and technical limitations.
• Exploration of novel approaches like MR-guided radiotherapy, proton therapy, immunotherapy integration, and AI-driven patient selection.

Main Results:

• SABR has demonstrated survival improvements in oligometastatic disease across various cancer types, though CRC patient representation is limited.
• SABR offers excellent local control and low toxicity in the oligometastatic setting.
• CRC metastases exhibit radioresistance, and outcomes vary based on tumor biology and prior treatments.

Conclusions:

• SABR is a viable treatment option for oligometastatic CRC, but CRC-specific Phase III trials are necessary.
• Advancements in technology and systemic treatments are crucial for overcoming current SABR limitations in CRC.
• An integrated approach incorporating SABR with novel strategies holds potential for improving outcomes in oligometastatic CRC.